Repros Therapeutics

Repros Therapeutics — Investor Presentation (November 2015)

40 slides from Repros Therapeutics's investor presentation, Nov 17, 2015

  1. Slide 1: Enclomiphene (EnCyzix): A Mechanistically Consistent Approach to Secondary Hypogonadism

    Enclomiphene ( EnCyzix ™) A Mechanistically Consistent Approach to the Treatment of Secondary Hypogonadism

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements made by the Company that are not historical facts contained in these slides (or in any oral accompanying discussion) are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertai

  3. Slide 3: Age-Related Hypogonadism

    CM - 3 Age - Related Hypogonadism In recent years, use of testosterone therapies has increased markedly among middle - aged and elderly men for a controversial condition that the FDA calls “ age - related hypogonadism , ” also referred to as “ late onset hypogonadism , ” a condition which is typical

  4. Slide 4: Increasing Number of Prescription Claims for Testosterone Products

    CM - 4 Increasing Number of Prescription Claims for Testosterone Products from U.S. Outpatient Retail Pharmacies, Stratified According to Age, 2010 – 2013 Nguyen et al N Eng J Med 2015

  5. Slide 5: Global Prevalence of Obesity in Adults 1980-2013

    CM - 5 Global, Regional, and National Prevalence of Obesity in Adults During 1980 - 2013: Global Burden of Disease Study 2013 - Obesity Does not Increase with Age >60 Yr Ng et al, Lancet 2014

  6. Slide 6: Categorising Gonadal Status by Testosterone and LH in EMAS

    Categorising Gonadal Status by Testosterone (T) and LH in the European Male Ageing Study (EMAS) : A General Population Observational Cohort Study Thresholds for abnormal: <Total T 10.5 nmol /L (300 ng/ dL ) and >LH 9.4 U/L (Tajar et al J Clin Endocrinol Metab 2010 95:1810) 0 20 40 60 80 LH (U/L) 0 1

  7. Slide 7: BMI and Age: Different Effects on Hormones

    CM - 7 EMAS Wu, JCEM 2008 BMI and Age: Different Effects on Hormones Increasing BMI is associated with progressively lower testosterone levels, independent of age Increasing age is associated with progressively higher LH levels, independent of BMI Testosterone ( nmol /L) LH (U/L)

  8. Slide 8: Risk Factors for Secondary Obesity Related Hypogonadism

    CM - 8 Risk Factors Age ( yrs ) BMI ≥ 25 - <30 kg/m 2 BMI ≥ 30 kg/m 2 Smoking ( current) Alcohol ( frequent) Co - morbidity ( ≥ 1) 0 5 10 15 *** *** * Adjusted Relative Risk Ratio Secondary Obesity Related Hypogonadism EMAS Tajar, JCEM 2010 0 5 10 15 *** Hypogonadism of Aging * p<0.05 *** p<0.001 Pr

  9. Slide 9: Mechanisms Controlling Testicular Function

    CM - 9 Mechanisms Controlling Testicular Function 9 Hypothalamus Pituitary Androgen Effects Fertility Estradiol (E 2 ) DHT GnRH LH FSH + + + + - T + Testis + - Leydig cells Sertoli cells Testosterone ( T) Spermatogenes is T T

  10. Slide 10: Exogenous Testosterone for Secondary Hypogonadism

    CM - 10 Exogenous Testosterone for Secondary Hypogonadism 10 Hypothalamus Pituitary Androgen Effects Fertility Estradiol (E 2 ) DHT GnRH LH FSH + - T + Testis Leydig cells Sertoli cells Testosterone ( T) Spermatogenes is T T Exogenous Testosterone Suppresses the HPG Axis

  11. Slide 11: What Do We Know About Men Seeking Treatment for Hypogonadism?

    CM - 11 So What Do We Know About the Current Group of Men Seeking Treatment for Hypogonadism?  The majority are secondary hypogonadal and are fertile  Confirmatory diagnosis not practiced in the US  No studies conducted by hormone replacement sponsors to assess impact on spermatogenesis  “But th

  12. Slide 12: Units of Testosterone and Clomiphene Sold

    Units of Testosterone and Clomiphene Sold 0 200 400 600 800 1000 1200 0 5000 10000 15000 20000 25000 30000 35000 40000 45000 Mar Apr May June July Aug Sep Oct Nov Dec Jan Feb Mar Apr May June July Aug Sep Oct Nov Dec Jan Feb Units of Clomiphene Sold (000) Units of Testosterone Sold (000) Monthly Uni

  13. Slide 13: ZA-304 & ZA-305 Results: Enclomiphene Yields Reproducible Outcomes

    ZA - 304 & ZA - 305 Results Enclomiphene Yields Meaningful Reproducible Outcomes Study ZA - 304 (p - values Treatment vs Enclomiphene) ZA - 305 (p - values Treatment vs Enclomiphene) Treatment Enclomiphene Androgel Placebo Enclomiphene Androgel Placebo N 41 43 45 44 42 41 Age (SD) 49.1 (7.4) 47.4 (7

  14. Slide 14: How Enclomiphene Works

    How Enclomiphene Works Enclomiphene blocks estrogen at the level of the H - P axis increasing LH levels which in turn increases endogenous production of T 0 1 2 3 4 5 6 7 Enclomiphene LH Androgel LH Median LH ( mIU /mL) Impact on LH in 16 Wk Study ZA - 304 Baseline End of Study 0 50 100 150 200 250

  15. Slide 15: No Negative Effects on Spermatogenesis Unlike Exogenous T

    Enclomiphene Exhibits No Negative Effects on Spermatogenesis Unlike Exogenous T -70 -60 -50 -40 -30 -20 -10 0 10 20 % Change from Baseline Impact on Sperm Concentration After 16 Wks Treatment ZA - 304 Enclomiphene Androgel Placebo 0 10 20 30 40 50 60 % of Oligospermic Subjects % of Subjects Becoming

  16. Slide 16: Percent Change in Testicular Volume by Orchidometry

    5.1 6.8 - 6.8 - 2.2 10.7 5.4 -8 -6 -4 -2 0 2 4 6 8 10 12 ZA-304 ZA-305 Mean Percent Change from Baseline Enclomiphene AndroGel Placebo Percent Change in Testicular Volume by Orchidometry vs. AndroGel p = 0.0074 vs. AndroGel p = 0.0224 n = 41 43 45 44 42 41

  17. Slide 17: Enclomiphene Averages Percent of Men in Normal Range

    Enclomiphene Averages > 75 % of Men Studied in Normal Range • 10 studies conducted with durations up to 1 year • Table determined as LOCF for morning T Study Subjects Receiving Enclomiphene Study Duration % Morning T in Normal Range (LOCF) ZN - 018 22 2 Wks. 77.3 ZA - 003 97 3 Mo. 63.9 ZA - 203 57 3

  18. Slide 18: Is There Anything Else to Worry About if I Take T?

    CM - 18 “So is there anything else to worry about if I take T?”  “I don’t want to have any more kids”  You have a reversible disorder if you are willing to make a lifestyle change  If you start taking testosterone you may need to take it for the rest of your life

  19. Slide 19: Obesity Related Hypogonadism is a Reversible Disorder

    Obesity Related Hypogonadism is a Reversible Disorder Treatment with Exogenous T “May require lifelong therapy” (Bayer abstract quote) Camacho et al. European Journal of Endocrinology 2013 n = 2395, *p<0.05, **p<0.01 Reported 15% Wt. Loss over 6 yrs. Source: Bayer - Schering Registry Study

  20. Slide 20: Conclusions: Clinical Implications

    CM - 20 Conclusions: Clinical Implications  Diagnostic differentiation of secondary from primary hypogonadism is essential – measure T and LH – The commonest form of T deficiency in ‘aging’ men is Secondary Hypogonadism associated with obesity (independent of aging) due to reversible functional sup

  21. Slide 21: Why Not Just Use Clomid?

    Why Not Just Use Clomid ? Enclomiphene (Patented) Trans Isomer (Pure Estrogen Antagonist) of Clomiphene Commercial Clomid (60% Trans, 40% Cis) 0 20 40 60 80 100 0.01 1 100 10000 % Concentration ( nM ) Estrogen Receptor Binding Affinity zu en Trough Concentration of Enclomiphene In Serum at Steady St

  22. Slide 22: Enclomiphene and Zuclomiphene Accumulate Differently in Tissues

    Enclomiphene and Zuclomiphene Clear and Accumulate Differently in Different Tissues 0 10000 20000 30000 40000 50000 60000 70000 80000 4 hrs post dose 24 hrs post dose Change in Tissue Concentration After Single 20 mg Dose of 14 C Labeled Drug to a Mouse (ng/gm of tissue) Zu Lymph Nodes En Lymph Node

  23. Slide 23: Enclomiphene and Zuclomiphene Accumulate Differently in Tissues

    Enclomiphene and Zuclomiphene Clear and Accumulate Differently in Different Tissues 0 1000 2000 3000 4000 5000 6000 7000 8000 4 hrs post dose 24 hrs post dose Change in Tissue Concentration After Single 20 mg Dose of 14 C Labeled Drug to a Mouse (ng/gm of tissue) Zu Eyes En Eyes Zu Pigmented Skin En

  24. Slide 24: Zuclomiphene Negatively Affects Organ Size in Mice

    0 0.5 1 1.5 2 2.5 Testes Kidney Percent Body Weight Placebo 4 mg ENC 40 mg ENC 4 mg ZU 40 mg ZU Both doses of zuclomiphene , p value < 0.03 compared to controls for both organs Impact of 90 Day Administration of 4 & 40 mg/kg of Either Enclomiphene or Zuclomiphene to Male Mice (n=15/group) Both Doses

  25. Slide 25: Enclomiphene Advantages vs Approved Hormone Replacement

    Enclomiphene Exhibits Unique Profile with Numerous Advantages vs Approved Hormone Replacement • The Enclomiphene Advantages – Oral – Not controlled substance, cannot be abused – No supernormal levels of T achieved – No transference risk – Restores normal function (no loss of testicular function ) –

  26. Slide 26: Size of Overweight and Obese US Population

    Size of Overweight and Obese US Population It is more than a sex issue 83,740,000 Males Age 20 - 60 58,620,000 Overweight or Obese 28,470,000 Metabolic Syndrome 1,700,000 Symptomatic (libido, etc.) Overweight or Obese Estimates based on CDC, EMAS and Sponsor Data

  27. Slide 27: Enclomiphene Regulatory Status

    Enclomiphene Regulatory Status • NDA filed with FDA – Treatment of secondary hypogonadism in overweight men – FDA cancelled public Advisory Committee Meeting citing use of CLIA certified lab did not meet rigorous guidance for pharmokinetic data – Enclomiphene is not testosterone • Enclomiphene pharm

  28. Slide 28: 24 Hour Serial Testosterone and Pharmacokinetics

    OT - 28 0 100 200 300 400 500 600 0 2 4 6 8 10 12 14 16 18 20 22 24 Mean Testosterone (ng/ dL ) Hours Post Dosing Phase 3 24 Hr Serial Testosterone Enclomiphene (n=298) AndroGel (n=75) Placebo (n=158) Unlike Topical Testosterone Administration There is No Temporal Relationship Between Time of Enclom

  29. Slide 29: Proellex Status and Plans Going Forward

    Proellex Status and Plans Going Forward • Ongoing Phase 2b Proellex studies – Uterine fibroids (vaginal and oral administration studies) • Rapid and maintained reduction in bleeding • Reduction of fibroid bulk • Reduction of bulk associated symptoms – Endometriosis • Rapid reduction in menstrual and

  30. Slide 30: Proellex for Uterine Fibroids and Endometriosis

    Proellex for the Treatment of Uterine Fibroids and Endometriosis • Over 30 million women of reproductive age in the US afflicted with symptomatic uterine fibroids or endometriosis • Over 300,000 hysterectomies performed every year in the US to treat these two disorders • No acceptable chronic therap

  31. Slide 31: Effective Dose of Proellex Stops Menstruation in Majority of Women

    An Effective Dose of Proellex Stops Menstruation in Majority of Women 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg % of Women with Induced Amenorrhea Proellex induced amenorrhea Mimics early follicular phase Without progesterone

  32. Slide 32: 12.5 mg Oral Proellex Induces Consistent Amenorrhea

    12.5 mg Oral Proellex Induces Consistent Amenorrhea in 3 Month Phase 2 Study 0 10 20 30 40 50 60 70 80 90 100 % % of Women Experiencing Any Menstrual Flow Over 3 Month Study Placebo 12.5 mg p< 0.0001 N= 40/arm

  33. Slide 33: Phase 1/2 Endometriosis Trial: Effect on Estradiol

    -50 0 50 100 150 200 250 300 Baseline Month 3 Month 6 Estradiol ( pg /mL) Lupron 12.5mg Proellex ZPE - 002 Phase 1/2 Endometriosis Trial Effect on Estradiol Over Time

  34. Slide 34: Endometriosis Trial Bone Resorption Marker

    ZPE - 002 Phase 1/2 Endometriosis Trial Bone Resorption Marker ( β - Cross Laps) 0 0.1 0.2 0.3 0.4 0.5 0.6 Baseline Month 3 Month 6 Lupron 12.5 mg Proellex Lupron 3 mo v.s . BL p = 0.023 Proellex mo 3 & 6 v.s . BL p NS n=10 Β - cross laps (ng/mL) n=9

  35. Slide 35: European POC Endometriosis Trial BMD Z Scores

    European POC Endometriosis Trial BMD – Z Scores Femoral Neck -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 Baseline Mo3 Mo6 Z Score Lucrin Proellex 12.5 mg No Statistically significant differences

  36. Slide 36: Vaginal Proellex to Eliminate Need for Hysterectomy

    Vaginal Proellex to Eliminate the Need for Hysterectomy in Most Situations • Initial Phase 2 study tested four doses of vaginal administration in the treatment of uterine fibroids completed – Assess reduction of fibroid size and elimination of symptoms – Top line data reported • FDA required additio

  37. Slide 37: Vaginal Proellex PBAC Scores Over Time

    Vaginal Proellex (ZPV - 200) PBAC Scores Over Time (n=39) 0 10 20 30 40 50 60 70 80 90 Baseline 4 Weeks 8 Weeks 12 Weeks (LOCF) PBAC Score (mL Blood per Period) Median Vaginal Proellex Pictorial Blood Loss Score (LOCF) Vaginal Proellex

  38. Slide 38: Proellex Open Label Update (12mg dose)

    ZPV - 200 Ext. Proellex Open Label Update (12mg dose) 0 10 20 30 40 50 60 70 80 90 100 Baseline End of 1st Cycle End of 2nd Cycle % of Initial Volume 12mg in initial treatment (n=15 fibroids) 3 or 6mg in initial treatment (n=14 fibroids) Paired Comparison for Subjects Dosed at 12 Throughout Study •

  39. Slide 39: Off Drug Interval Treatment Strategy

    “Off Drug Interval” Treatment Strategy 4 Month Dosing Cycle 4 Month Dosing Cycle 4 Month Dosing Cycle Off Drug Interval to allow for: • Menses • Refresh the endometrium • Experience to date suggests menses returns in 25 - 35 days Continue as needed Concept has been accepted by the FDA as noted in En

  40. Slide 40: Financial Summary

    Financial Summary • Cash and equivalents: (unaudited end of Q3 2015) $26.2 M • Cash used in 2015 (through September 30, 2015) : $20.4 M • Cash runway: YE 2016 • Current shares outstanding: 24.3 M shares – Warrants Outstanding – Series A – 2,502 (purchased in unit deal @ $2.45); Series B – 429,704 @

Repros Therapeutics — Investor Presentation (November 2015) on 6ix